Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Company Overview

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements. The technology has been incorporated into multiple approved therapies, including subcutaneous formulations of treatments for cancer and immune-related conditions. Halozyme also markets Hylenex recombinant, a human hyaluronidase product used to improve the absorption and dispersion of other injected medicines and fluids.

Founded in 1998 and headquartered in San Diego, California, Halozyme serves global pharmaceutical markets through its commercial operations and partnerships with drug developers in the United States and internationally. The company’s business model is centered on developing its proprietary delivery platform, licensing it to partners, and supporting the development and commercialization of products that use the technology.

Key Stats

• Today's Range: $106.34 to $108.23
• 50-Day Range: $75.05 to $110.76
• 52-Week Range: $61.22 to $111.15
• Volume: 861,533 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $12.17 billion
• P/E Ratio: 32.00
• Dividend Yield: N/A
• Price Target: $91.20
• Consensus Rating: Moderate Buy

Halozyme Therapeutics Stock Analysis - MarketRank™

Halozyme Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 324th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Halozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and 1 sell rating.

Downside Risk

Halozyme Therapeutics has a consensus price target of $91.20, representing about 14.9% downside from its current price of $107.20.

Amount of Analyst Coverage

Halozyme Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 13.09%

Earnings Growth

Earnings for Halozyme Therapeutics are expected to grow by 13.09% in the coming year, from $8.25 to $9.33 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Halozyme Therapeutics is 32.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Halozyme Therapeutics is 32.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Earnings Growth Ratio

Halozyme Therapeutics has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Halozyme Therapeutics has a P/B Ratio of 255.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.45% of the float of Halozyme Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Halozyme Therapeutics has a short interest ratio ("days to cover") of 8.69.

Change versus previous month

Short interest in Halozyme Therapeutics has recently increased by 1.67%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Halozyme Therapeutics does not currently pay a dividend.

Dividend Growth

Halozyme Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.02

News Sentiment

Halozyme Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Halozyme Therapeutics this week, compared to 9 articles on an average week.

Search Interest

Only 5 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,370,004.00 in company stock.

Percentage Held by Insiders

2.50% of the stock of Halozyme Therapeutics is held by insiders.

Percentage Held by Institutions

97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/13/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/16/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HALO
• CIK: 1159036
• Web: www.halozyme.com
• Phone: 858-794-8889
• Fax: 858-704-8311
• Employees: 423
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Halozyme Therapeutics: $91.20
• High Price Target: $115.00
• Low Price Target: $56.00
• Potential Upside/Downside: -14.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.35
• Trailing P/E Ratio: 32.00
• Forward P/E Ratio: 12.99
• P/E Growth: 0.41
• Net Income: $316.89 million
• Net Margins: 24.86%
• Pretax Margin: 35.06%
• Return on Equity: 260.98%
• Return on Assets: 23.91%

Debt

• Debt-to-Equity Ratio: 13.50
• Current Ratio: 2.71
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $1.66 billion
• Price / Sales: 7.31
• Cash Flow: $4.77 per share
• Price / Cash Flow: 22.47
• Book Value: $0.42 per share
• Price / Book: 255.24

Miscellaneous

• Outstanding Shares: 113,498,000
• Free Float: 110,661,000
• Market Cap: $12.17 billion
• Optionable: Optionable
• Beta: 0.88